Goldan Keith A. 4
4 · Syndax Pharmaceuticals Inc · Filed Jul 18, 2025
Insider Transaction Report
Form 4
Goldan Keith A.
Chief Financial Officer
Transactions
- Sale
Common Stock
2025-07-16$9.29/sh−1,296$12,033→ 92,450 total
Footnotes (1)
- [F1]Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units.